Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.
PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.
Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.
BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.
BiomX (NYSE American: PHGE) announced a securities purchase agreement to issue and sell 30,608,163 shares at $0.245 per share, raising approximately $7.5 million through a private investment in public equity (PIPE) financing. The financing will close in two parts: $1.5 million expected soon, and the remainder pending stockholder approval in Q2 2023. Proceeds will fund clinical development of BX004 for lung infections in cystic fibrosis patients and other programs. The shares are unregistered under the Securities Act and may not be sold in the U.S. without proper registration.
BiomX has reported positive results from Part 1 of its Phase 1b/2a trial for BX004, a phage therapy targeting chronic pulmonary infections in cystic fibrosis patients caused by Pseudomonas aeruginosa. The therapy was found to be safe and well-tolerated across all patients, with preliminary efficacy signals noted, including a significant reduction in bacterial burden of 1.42 log10 CFU/g compared to placebo. Patient dosing for Part 2 has commenced, with results expected in Q3 2023. This trial marks a significant advancement as the first double-blind placebo-controlled study showcasing the effectiveness of a phage-based treatment for this condition.
BiomX Inc. (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022. The virtual presentation is scheduled for 10:30 AM EST.
BiomX is innovating in the microbiome sector with novel phage therapies targeting specific pathogenic bacteria. The presentation will be available via the Company’s website.
BiomX (PHGE) has made progress in enrolling patients for its Phase 1/2 trial of BX004, targeting lung infections in cystic fibrosis. Following challenges in patient recruitment due to COVID-19, enrollment is now expected to complete by year-end, with initial results anticipated in Q1 2023. The company reported a cash balance of $41.5 million, sufficient to support operations until at least mid-2024. Notably, it received a $5 million Therapeutics Development Award from the Cystic Fibrosis Foundation, bolstering its financial position.
BiomX Inc. (PHGE), a clinical-stage microbiome company, announced a conference call on November 9, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and provide business updates. The conference will be accessible via phone or through a live audio webcast on the company's website. BiomX focuses on developing natural and engineered phage therapies aimed at treating chronic diseases by targeting specific pathogenic bacteria. More details can be found on their website.
BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 AM EST. The conference runs from September 12-14, 2022. Presentations will be available on-demand, and the webcasts can be accessed via the BiomX Investors section post-event. The company focuses on developing phage therapies targeting pathogenic bacteria to treat chronic diseases.
BiomX (PHGE) updates on its Phase 1b/2a trial for BX004, targeting lung infections in cystic fibrosis (CF), with results expected by Q3 2022. The company entered a collaboration with Boehringer Ingelheim to discover microbiome markers for inflammatory bowel disease. BiomX published significant research articles, including one in Cell, and has extended its cash runway through mid-2024 with a current cash position of $46.7 million. Despite a net loss of $7.5 million in Q2 2022, the company is focused on key milestones to enhance shareholder value.
BiomX Inc. (NYSE American: PHGE) announced a conference call on August 10, 2022, at 8:00 a.m. EDT to discuss its second-quarter financial results and business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria for chronic disease treatment. Investors can participate by calling a designated number or accessing the webcast through the company's website.
BiomX Inc. (PHGE) announced the publication of a significant study confirming the efficacy of its phage therapy candidate BX003 targeting Klebsiella pneumoniae in inflammatory bowel disease (IBD). Conducted with leading academic institutions, the research demonstrated safety and tolerability in a Phase 1a trial, as well as effective suppression of pathogenic bacteria in colitis-prone mice. The findings enhance the scientific basis for BX003’s potential in treating IBD, emphasizing collaboration in advancing treatment for challenging diseases.
BiomX Inc. (NYSE American: PHGE) announced its decision to voluntarily delist from the Tel Aviv Stock Exchange (TASE), effective October 6, 2022. This move is based on a review of trading volumes and the costs associated with maintaining multiple exchange listings. BiomX believes that consolidating its listing to the NYSE American is in the best interest of shareholders. Following the delisting, all shares on the TASE will transition to continue trading on the NYSE American.